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Abstract
Background Nonsteroidal anti-inflammatory drugs have an inhibitory role in pathogenesis of pancreatitis. Guidelines from the
European Society of Gastrointestinal Endoscopy recommend routine rectal administration of 100 mg of diclofenac or indometh-
acin immediately before or after ERCP for all patients without contraindications.
Aims Our aim was to evaluate the effect of diclofenac in preventing post-ERCP pancreatitis (PEP) in a high-volume, low-PEP-
risk ERCP unit.
Methods The rate and severity of PEP were compared in groups of 1000 historical controls prior to the routine use of diclofenac
and in 1000 patients receiving 100 mg diclofenac before ERCP.
Results PEP occurred in 56 (2.8%) of the 2000 patients, and the rate of the pancreatitis was 2.8% in control group and 2.8% in
diclofenac group (p = 1.000). The PEP rate among the native papilla patients was 3.9% in control group and 3.6% in diclofenac
group (p = 0.803). In subgroup analysis of patients with a high risk of PEP, diclofenac neither prevented PEP nor made its course
milder.
Conclusions In an unselected patient population in a center with a low incidence of PEP, diclofenac seems to have no beneficial
effect.
Keywords Acute pancreatitis . Diclofenac . ERCP . ESGE
recommendation . Post-ERCP pancreatitis
Introduction
Acute pancreatitis is the most frequent and feared complica-
tion of endoscopic retrograde cholangio-pancreatography
(ERCP). The occurrence of post-ERCP pancreatitis (PEP)
varies between 1 and 25% depending on risk factors and the
indication of ERCP.1–4 The vast majority of PEP has a mild or
moderate course, but in 0.3–0.6% of cases, PEP is severe in
nature with a need for intensive care and invasive interven-
tions, and at worst, it can even lead to death.2, 5, 6 The patho-
genesis of PEP is not clearly understood. Phospholipase A is
believed to play a key role in the inflammatory cascade lead-
ing to pancreatitis. Nonsteroidal anti-inflammatory drugs
(NSAIDs) are potent inhibitors of phospholipase A2 activity,
and neutrophil and endothelial cell attachment. With this
mechanism, they are believed to play an inhibitory role in
the pathogenesis of pancreatitis.7, 8 The guidelines from the
European Society of Gastrointestinal Endoscopy (ESGE)9
recommend routine rectal administration of 100 mg of
diclofenac or indomethacin for all patients without contrain-
dications immediately before or after ERCP. This guideline is
based on eight meta-analyses that all show the benefit of
NSAIDs in preventing PEP.10–17 The studies in these meta-
analyses have strict inclusion and exclusion criteria, and they
have mainly been conducted on high-risk patients and proce-
dures. The overall risk of PEP in these studies has been rather
high (6.9–26%) due to their patient selection.18–26 The
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recommends rectal indomethacine for the prevention of PEP
in average-risk individuals.27 In Asia, Japanese guidelines rec-
ommend administration of intrarectal NSAIDS for all cases
undergoing ERCP with no contraindications.28
Commonly known NSAID-related adverse events are gas-
trointestinal bleeding, ulcer, and perforation as well as adverse
events in renal function. However, single dose of NSAIDS in
preventing PEP has been safe in earlier studies.19, 20 On the
basis of the ESGE guidelines and earlier research data, we
initiated rectal administration of diclofenac to all eligible pa-
tients without contraindications referred for ERCP at Helsinki
University Hospital (HUH) after November 2013.
The aim of this study was to evaluate the effect of
diclofenac in preventing PEP in a high-volume, low-PEP-
risk ERCP unit. The annual volume in our unit is 1200
ERCP procedures, and the overall risk of PEP has varied be-
tween 2.0 and 3.3%.29, 30
Materials and Methods
In this study, we retrospectively compared 1000 patients who
had been rectally administered 100 mg diclofenac before un-
dergoing ERCP (diclofenac group (DG)) to 1000 patients who
had not received administration of diclofenac (control group
(CG)). Both groups included all the adult patients (≥18 years)
procedures who were referred to our unit, regardless of the
indications for ERCP. The exclusion criteria for DG were
contraindications for NSAIDs (renal insufficiency or NSAID
allergy). To collect the data for this study, all patient records
about ERCP patients were reviewed, and information about
age, sex, weight, height, and history of acute pancreatitis,
chronic pancreatitis, or PEP were recorded. The results of
laboratory tests, including plasma bilirubin and amylase levels
before ERCP, were collected, as well as plasma amylase levels
4 h after ERCP and, if the patient stayed overnight, 24 h after
ERCP. All the ERCP-related details were explored: indication,
type and difficulty of procedure, type of cannulation, duration
of cannulation of native papillae, pancreatic duct
opacification, and duration of ERCP. The difficulty of the
procedure was scored using the scale presented by Cotton
et al.31 Biliary cannulation of native papilla was defined as
Bdifficult^ if there were more than five attempts, the guide
wire passed into the pancreatic duct two times or the primary
cannulation was unsuccessful after 5 min. Data about biliary
duct cannulation time was available only for 506 patients of
the 934 native papilla patients whose bile duct cannulation
was attempted. Therefore, we also interpreted the cannulation
as difficult if there was a need for a second cannulation meth-
od to get access to the bile duct. The time of hospitalization
was recorded, and the patient history was followed 30 days
after ERCP to explore possible readmissions due to ERCP-
related adverse events or late onset of PEP.
PEP was diagnosed if there was an elevation in amylase
exceeding three times the upper limit of normal four or 24 h
after the procedure with pancreas-specific abdominal pain re-
quiring hospitalization or prolonging initial discharge from
hospital by more than 1 day.32 The severity of PEP was clas-
sified according to the revised Atlanta consensus criteria.33
Other adverse events, such as perforation and bleeding, were
classified according to the Cotton consensus criteria.32, 33
Perforation was defined if there was a visible leak of contrast
dye or a suspicion of guide wire perforation during the ERCP,
or if air and fluids were visible in a computed tomography
(CT) scan after ERCP.
All ERCP procedures were performed or supervised by
four experienced interventional operators who each undertake
around 300 ERCPs a year. Their individual rate of PEP varied
between 2.7 and 3.6% in this study.
The primary outcome of this study was to assess the inci-
dence of PEP in the CG and DG, as well as in known higher-
risk subgroups, such as patients with native papillae, pancre-
atic sphincterotomies, papillectomies, pancreatic brush cytol-
ogy, normal bilirubin level, difficult biliary cannulation, and
female patients. The secondary outcomewas to resolve weath-
er the administration of diclofenac makes the course of PEP
milder.
In previous analyses, the risk of PEP in our unit has been
2.0–3.3%.29, 30 The sample size determination for this study
was carried out as follows: power = 0.8;α = 0.05; and to lower
the risk from 3.0 to 1.0% needs a sample of 1528 patients
(764 + 764). We included 2000 patients in this study. The
analysis was performed using SPSS version 22.0 (IBM
Corporation, Somers, NY) statistical software. Differences in
demographic variables between the CG and the DG were an-
alyzed using the chi-square test or Fisher’s exact test for cat-
egorical variables and the nonparametric Wilcoxon-Mann-
Whitney test for continuous variables. The same tests were
used to further analyze the associations between variables
and PEP. To show the effect of diclofenac in groups with risk
factors for PEP, each individual risk subgroup was separately
adjusted for diclofenac administration in a logistic regression
analysis. In addition, all variables that had p < 0.05 in the
univariate analysis were selected for multivariate logistic re-
gression analysis in order to identify potential confounding
variables for PEP. The results were presented as odds ratios
(ORs) with 95% confidence intervals (95% CIs). Probabilities
below 0.05 were regarded as statistically significant.
Results
Most of the ERCPs were therapeutic procedures (97%). The
most common procedure was a biliary sphincterotomy, and it
was performed 1327 times. After the sphincterotomy, the most
common procedures were biliary stent placement or removal
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(749) and biliary stone removal (459). Half of the patients
(1058) had native papillae, and the median cannulation time
of native papilla was 92 s. The median total time of the pro-
cedure was 21 min in all patients, as it was 21 min in native
papilla cases as well. According to the criteria used, the biliary
cannulation of native papilla was rated as difficult in 328 cases
(31%).
The baseline characteristics of the study groups (CG and
DG) are shown in Table 1. The possible patient-related risk
factors for PEP were similar in these two groups with four
exceptions. (1) Sixteen patients in the CG and only 6 patients
in the DG had a history of earlier PEP (p = 0.032). This patient
group was very small, and therefore, the result has no clinical
relevance. (2) More pancreatic sphincterotomies were
Table 1 Patient and procedure





Agea (years) 63 (18–100) 64 (18–97) 0.358
Female, n (%) 421 (42.1) 430 (43) 0.684
ASA grade, n (%) 0.697
1 31 (3.1) 39 (3.9)
2 244 (24.4) 215 (21.5)
3 536 (53.6) 589 (58.9)
4 189 (18.9) 157 (15.7)
BMIa (kg/m2) 24.8 (12.8–56.2) 24.8 (12.4–56) 0.897
Normal serum bilirubin, n (%) 521 (52) 505 (51) 0.315
Native papilla, n (%) 535 (53.5) 523 (52.3) 0.624
History of acute pancreatitis, n (%) 137 (13.7) 142 (14.2) 0.747
History of post-ERCP pancreatitis, n (%) 16 (16) 6 (6.0) 0.032
ERCP gradeb, n (%) 0.814
1 61 (6.1) 79 (7.9)
2 546 (54.6) 495 (49.5)
3 274 (27.4) 334 (33.4)
4 119 (11.9) 92 (9.2)
Indication, n (%)
Biliary stone 286 (28.6) 293 (29.3) 0.762
Biliary stricture 399 (39.9) 412 (41.2) 0.566
PSC 4 (0.4) 8 (0.8) 0.247
Bile duct injury after cholecystectomy 38 (3.8) 20 (2.0) 0.016
Problems after liver transplantation 36 (3.6) 14 (1.4) 0.002
Chronic pancreatitis 216 (21.6) 209 (20.9) 0.702
Pancreatic pseudocyst 99 (9.9) 84 (8.4) 0.239
Papillectomy 12 (1.2) 12 (1.2) 1.000
Therapy, n (%)
Biliary stent 368 (36.8) 381 (38.1) 0.483
Biliary sphincterotomy 500 (50.0) 468 (46.8) 0.133
Biliary stone removal 218 (21.8) 240 (24.0) 0.124
Precut 15 (1.5) 18 (1.8) 0.593
Pancreatic sphincterotomy 192 (19.2) 158 (15.8) 0.045
Pancreatic stent 239 (23.9) 258 (25.8) 0.313
Pancreatic brush cytology 32 (3.2) 41 (4.1) 0.340
Pseudocyst transmural drainage 18 (1.8) 17 (1.7) 0.860
Papillectomy 12 (1.2) 12 (1.2) 1.000
Difficult biliary cannulation, native papilla, n
(%)
168 (31.4) 160 (30.6) 0.629
Pancreatic duct opacification, n (%) 332 (33.2) 347 (34.7) 0.479
Duration of procedure (min)a 21 (3–153) 21 (2–148) 0.005
Duration of cannulation, native papilla (s)a 105 (0–3720) 91 (0–3030) 0.421
Length of hospital stay after ERCPa 1 (0–106) 1 (0–87) 0.015
Operator, n (%) 0.000
1 JH 332 (33.2) 200 (20.0)
2 LK 252 (25.2) 211 (21.1)
3 OL 168 (16.8) 211 (21.1)
4 MU 195 (19.5) 173 (17.3)
5 Trainee involvement in ERCP 53 (5.3) 205 (20.5)
ASA American Society of Anesthesiology, BMI body mass index, ERCP endoscopic retrograde
cholangiopancreatography, PSC primary sclerosing cholangitis
a Data are presented as numbers and (%) percentages of patients or as median (range)
b ERCP grade according to Cotton classification
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performed in the CG (192 patients) than in the DG (158 pa-
tients, p = 0.045). (3) The median duration of the procedure
was 21 min in both groups; however, in the CG, 117 opera-
tions took longer than 45 min compared to the DG with 143
operations lasting more than 45 min, and in the DG, the total
time of procedure was longer (p = 0.002). (4) Patients in the
CG stayed longer in hospital after ERCP than patients in the
DG (p = 0.015). The median time in both groups was 1 day,
but patients in DG were discharged more often on the day of
operation. The reason for this difference is the change of our
policy after having a new big daycare unit in our hospital,
which made it possible to discharge patients on the day of
procedure. However, there was no difference between the
groups in the number of inpatients after day 1 (p = 0.396).
The incidence of PEP in the different risk groups is shown
in Table 2. PEP occurred in 56 (2.8%) of the 2000 patients,
and its distribution was equal in both groups: 2.8% in the CG
and 2.8% in the DG (p = 1.000). The PEP rate among the
native papilla patients was 3.9% in the CG and 3.6% in the
DG (p = 0.803). There were no significant differences be-
tween the CG and DG groups in the distribution of any PEP
risk group (Table 2).
In univariate analyses, the risk factors for PEP were found
to be native papilla, pancreatic sphincterotomy, pancreatic
brush cytology, papillectomy, precut sphincterotomy, difficult
cannulation, and prolonged time of procedure (Table 3). We
chose these variables for pair-wise logistic regression analysis
together with the administration of diclofenac, which did not
have an effect on the risk of PEP in these analyses (data not
shown). We also carried out a multivariate analysis on these
risk factors and the administration of diclofenac. In multivar-
iate analysis, four factors were significantly associated with
the risk of PEP: pancreatic sphincterotomy, pancreatic brush
cytology, difficult cannulation, and prolonged time of proce-
dure. Administration of diclofenac did not show any effect on
the risk of PEP (Table 4).
In the whole cohort, 35 patients (1.8%) had mild PEP, 18
patients (0.9%) had moderately severe PEP, and three patients
(0.15%) had severe PEP according to the revised Atlanta
criteria. There was no difference between the groups in the
severity of PEP (p = 0.877) (Table 5).
Adverse events of ERCP other than PEP are shown in
Table 6. Significant bleeding after ERCP occurred in 15 pa-
tients (0.75%): ten incidents of bleeding in the CG and five
incidents in the DG. The bleeding was classified as severe in
ten patients. Most of the severe bleeding cases were mild to
moderate in nature, but because we promptly performed en-
doscopy and electrocoagulation of the bleeding site after
blood clot removal, they were categorized as a more severe
event. There was no association between bleeding and admin-
istration of diclofenac. There were 21 incidents of perforation
(1%) after ERCP. Seven were graded as a mild perforation,
seven as moderate, and seven as severe. The reason for the
perforation was guide wire perforation in nine patients,
sphincterotomy in six patients, papillectomy in two patients,
biliary dilatation with biliary stones in two patients, duodenal
Table 2 Incidence of
postendoscopic retrograde
cholangiopancreatography
pancreatitis according to risk
factors
Risk factors n/N (%) CG DG p
Native papilla 21/535 (3.9) 19/523 (3.6) 0.803
Female sex 13/408 (3.2) 14/416 (3.4) 0.889
Native papilla, female 12/241 (4.9) 13/249 (5.2) 0.900
Native papilla, female under 40 years 1/24 (4.2) 0/28 (0) 0.462a
History of pancreatitis 2/137 (1.5) 2/142 (1.4) 1.000a
History of PEP 1/16 (6.3) 0/6 (0) 1.000a
Difficult biliary cannulation, native papilla 12/156 (7.7) 10/150 (6.7) 0.747
Duration of ERCP >40 min 12/ 145 (8.2) 9/169 (5.3) 0.3300
Normal serum bilirubin 14/457 (3.1) 10/485 (2.1) 0.330
Pancreatic sphincterotomy 17/192 (8.9) 12/158 (7.6) 0.671
Biliary sphincterotomy 21/500 (4.2) 13/468 (2.8) 0.230
Pancreatic duct dilatation 5/108 (4.6) 4/120 (3.3) 0.739a
Pancreatic stent placement 6/239 (2.5) 10/258 (3.9) 0.389
Pancreatic cytology 8/153 (5.2) 6/194 (3.1) 0.335
Pancreatic duct opacification 10/322 (3.1) 14/333 (4.2) 0.471
Precut 1/15 (6.7) 2/18 (11.1) 1.000a
Papillectomy 1/12 (8.3) 3/12 (25) 0.590a
Data are presented as numbers
n number of pancreatitis cases, N group size, % percentages
a Fisher’s exact test
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dilatation in one patient, and pharyngeal perforation in one
patient. Surgery was needed for only one patient with duode-
nal perforation; the others recovered after drainage and anti-
biotics, and in the cases of guide wire perforation, even with-
out any treatment. The incidents of perforation were equally
distributed between the CG and DG (11 and ten, p = 0.513).
Post-ERCP cholangitis was diagnosed in 15 patients (0.75%),
nine in the CG, and six in the DG (p = 0.71).
Prophylactic pancreatic stents were placed only 22 times to
prevent PEP. There were 11 stents in both groups. Indications
for prophylactic pancreatic stent were papillectomy in 11 pa-
tients and difficult cannulation in 11 patients (five biliary stone
removals, five biliary tumor strictures, and one biliary stricture
after liver transplantation). One patient with a prophylactic
stent had mild PEP.
The 30-day mortality was 3.1% (55 patients). The median
age of this group was 74 years (range 55–93). The most com-
mon cause of death was widely spread malignancy (44 pa-
tients). Other coexisting diseases, such as pneumonia or sep-
sis, were the cause of death in nine patients. Two patients
(0.1%) died due to complications from the ERCP; one patient
in the CG had a perforation due to a sphincterotomy and
biliary stone removal, and another had severe PEP (ages 93
and 87 years, respectively).
Discussion
The aim of our study was to determine the efficacy of prophy-
lactic rectal diclofenac in preventing PEP and reducing the
severity of its clinical course. We assessed the effects of
diclofenac on our unselected patient population. Statistical
analyses showed no difference in the risk or the severity of
PEP between the CG and DG in pair-wise logistic regression
analysis with known risk factors for PEP. In a multivariate
logistic regression analysis including patient- and process-
related risk factors, diclofenac did not have an effect in the
risk of PEP. The overall incidence of PEP in this study was
2.8%. According to our routine protocol, we measure plasma
amylase 4 h after the procedure from all ERCP patients. This
protocol may even increase the rate of PEP in our unit, even
though abdominal pain is needed for the diagnosis of PEP. In
centers where amylase is measured only in cases of abdominal
pain, mild cases of PEP that resolve spontaneously with
Table 3 Factors associated with postendoscopic retrograde
cholangiopancreatography pancreatitis, univariate analysis
OR (95% CI) p




BMI (kg/m2) 0.999 (0.95–1.050) 0.971






History of acute pancreatitis 0.136
No 0.93
Yes 1.98 (0.77–5.12)






























Pancreatic duct opacification 0.153
No 0.786
Yes 1.160 (0.92–1.46)
Duration of cannulation 1.000 (1.000–1.000) 0.172
Perforation
No 0.115
Yes 1.068 (0.99–1.14) 0.000
Duration of procedure 1.025 (1.01–1.04) 0.000
Operator 1.012 (0.82–1.24) 0.907
BMI body mass index
Table 4 Logistic regression analysis on the effect of diclofenac on the
risk of PEP when adjusting for the risk of PEP in a univariate analysis
OR (95%CI) P
Administration of diclofenac 1.031 (0.60–1.79) 0.913
Native papilla 1.099 (0.53–2.28) 0.800
Pancreatic sphincterotomy 2.857 (1.49–5.47) 0.002
Pancreatic cytology 3.189 (1.233–8.250) 0.017
Precut 1.125 (0.29–4.39) 0.865
Difficult biliary cannulation 2.145 (1.10–4.20) 0.026
Papillectomy 2.818 (0.788–10.08) 0.111
Duration of procedure 1.020 (1.01–1.03) 0.001
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painkillers may be missed. The risk of severe PEP in our
present study is 0.15% according to the Atlanta criteria.33
The low rate of PEP in our present study differs from the other
previous studies, which were conducted with a much higher
incidence of PEP, showing a clear effect of diclofenac or in-
domethacin in reducing the risk of PEP.18, 19, 21, 23, 25, 34 Three
other recently published randomized trials have similar results
to ours, showing no effect of indomethacin or diclofenac in
preventing PEP.22, 35, 36 However, they include a relatively
low number of patients (n = 144, n = 665, and n = 449, re-
spectively). Our cohort differs from these due to its larger
volume, with 2000 patients and 1056 native papillae. Our
results indicate that the role of NSAIDS in preventing PEP
is not clear and further randomized controlled trials are needed
to explore its routine use for all patients, especially in centers
with low PEP risk.
Absence of chronic pancreatitis, normal serum bilirubin,
and a previous episode of acute pancreatitis are known as
patient-related risk factors of PEP, and female patients are also
known to be at a higher risk. Procedure-related risk factors
include difficult cannulation, repeated contrast injection of
the pancreatic duct, pancreatic acinar opacification, and precut
or needle-knife sphincterotomy.2, 4, 5, 37 All kinds of mechan-
ical manipulation of the pancreatic duct can cause obstruction
of or prolonged spasms in the pancreatic sphincter. Although
our study is retrospective in nature and therefore has some
limitations, it involves a large cohort of patients and explores
the effects of diclofenac in our patients; our unit has been
keeping a thorough register of all ERCP procedures for sev-
eral years. These known PEP risk factors exist in our present
study: 1058 patients had native papilla (3.8% risk of PEP in
our study), 1026 patients had normal serum bilirubin (3.0%
risk of PEP), 279 patients had previous history of pancreatitis
(1.4% risk of PEP), difficult cannulation occurred 326 times
(6.7% risk of PEP), pancreatic sphincterotomy was performed
350 times (8.3% risk of PEP), and the rate of therapeutic
ERCPs was as high as 97%. The patient material was not
selected, with the exception of very few sclerosing cholangitis
patients, who are mainly treated in the gastroenterological
internal medicine endoscopic unit at our hospital, and patients
with sphincter of Oddi dysfunction, which seem to be scarce
in the Finnish population.
There were some differences between the patient character-
istics of the CG andDG. The variation of operators between the
groups is due to the trainees in our unit, especially two trainees
after November 2013 (DG). All trainees performing ERCPs
were supervised and assisted by the same four experienced
endoscopists, who carried out most of the ERCPs. All the pro-
cedures were performed in the same manner, and there were no
changes in the ERCP protocol during the study period. Trainees
were involved in the easiest procedures, and their risk of PEP
remained low (1.8–2.3%). Analyzing only the 1742 patients,
whose procedure was performed by the four experienced
endoscopists, the risk of PEP did not differ between CG and
DG, similar to the whole cohort (p = 0.939). More pancreatic
sphincterotomies were also performed in the CG than in the
DG (p = 0.045). Pancreatic sphincterotomy is a risk factor for
Table 5 Severity of postendoscopic retrograde cholangiopancreatography
pancreatitis (PEP) according to revised Atlanta criteria
All CG DG p
PEP, n (%) 56 (2.8) 28 (2.8) 28 (2.8) 1.000
Mild 35 18 (1.8) 17 (1.7) 1.000
Moderately severe 18 8 (0.8) 10 (1.0) 0.865
Severe 3 2 (0.2) 1 (0.1) 0.636
PEP in native papilla patients, n (%) 40 (3.8) 21 (4.1) 19 (3.8) 0.896
Mild 23 (2.2) 13 (2.4) 10 (1.9) 0.803
Moderately severe 14 (1.3) 6 (1.1) 8 (1.5) 0.564
Severe 3 (0.3) 2 (0.4) 1 (0.2) 0.561
Data are presented as number and (%) of patients
Table 6 Other endoscopic
retrograde
cholangiopancreatography-
related adverse events according
to Cotton classification
All CG DG p
Bleeding, n (%) 15 (0.75) 10 (1.0) 5 (0.5) 0.120
Mild 4 2 2
Moderate 1 0 1
Severe 10 8 2
Perforation, n (%) 21 (1) 12 (1.2) 9 (0.9) 0.513
Mild 7 4 3
Moderate 7 4 3
Severe 7 4 3
Cholangitis, n (%) 15 (0.75) 9 (0.9) 6 (0.6) 0.446
Mild 3 2 1
Moderate 12 7 5
Severe 0 0 0
Data are presented as numbers and (%) percentages of patients
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PEP, and therefore, it can distort the results. However, since in
this study, more pancreatic sphincterotomies were performed in
the CG, it does not interfere with the effects of the diclofenac.
The difference between the durations of the procedures be-
tween the groups can be explained partly by the initiation of
routine double-balloon ERCPs and cholangioscopies, which
our unit adopted in 2012. They are longer procedures, with
mean operating times of 59 and 72 min. There were only one
double-balloon ERCP and three cholangioscopy ERCPs in the
CG, whereas these numbers were 19 and 30 in the DG. Their
risk profile for PEP did not differ from the other procedures in
this study.
Conclusion
In an unselected patient population in a center with a low
incidence of PEP, diclofenac seems to have no beneficial ef-
fect on the risk of PEP.
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